Sanofi $SNY Stock: Quadrant Capital Group LLC Lowers Holdings

Quadrant Capital Group LLC reduced its stake in Sanofi (NASDAQ:SNY) by 81.4% in the 3rd quarter, Holdings Channel reports. The firm owned 7,607 shares of the company’s stock after selling 33,376 shares during the quarter. Quadrant Capital Group LLC’s holdings in Sanofi were worth $298,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in SNY. Manning & Napier Advisors LLC boosted its position in shares of Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after buying an additional 1,194,141 shares during the period. Bank of America Corp DE lifted its position in Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after acquiring an additional 940,342 shares in the last quarter. Regal Partners Ltd lifted its position in Sanofi by 33.2% during the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after acquiring an additional 633,782 shares in the last quarter. Royal Bank of Canada lifted its position in Sanofi by 17.5% during the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after acquiring an additional 470,882 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in Sanofi by 399.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock worth $15,270,000 after acquiring an additional 253,465 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $41.79 on Tuesday. The firm has a 50-day moving average of $42.38 and a two-hundred day moving average of $44.46. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The stock has a market cap of $101.32 billion, a P/E ratio of 21.88, a PEG ratio of 1.28 and a beta of 0.33. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The firm’s revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.24 earnings per share. On average, research analysts expect that Sanofi will post 5.00 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SNY has been the subject of several recent research reports. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research report on Thursday, September 17th. Berenberg Bank reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Thursday, October 1st. Finally, DZ Bank restated a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $49.50.

Sanofi Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.